Cardax, Inc.

CDXI

US14141D2018

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 14:38:51 27/12/2023 GMT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2021	Cardax, Inc. announced a financing transaction	CI
2021	Cardax, Inc. Announces Restructuring of Board of Directors	CI

Cardax, Inc. has Changed its Ticker to CDXI from CDXID

February 03, 2020 at 05:00 am

Effective February 03, 2020, Cardax, Inc. changed its Pink Sheets LLC stock ticker symbol to CDXI from CDXID.

Latest news about Cardax, Inc.

Cardax, Inc. announced a financing transaction	15/09/21	CI
Cardax, Inc. Announces Restructuring of Board of Directors	31/08/21	CI
Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/05/21	CI
Cardax, Inc. announced that it expects to receive $10 million in funding from US Capital Global Investment Management, LLC	10/01/21	CI
Cardax, Inc. announced that it expects to receive $10 million in funding	17/11/20	CI
Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	13/11/20	CI
Cardax, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	14/08/20	CI
Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	15/05/20	CI
Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	30/03/20	CI
Cardax, Inc. announced that it expects to receive $0.46 million in funding	15/03/20	CI
Cardax, Inc. has Changed its Ticker to CDXI from CDXID	03/02/20	CI
Cardax, Inc. announced that it expects to receive $0.25 million in funding from Harbor Gates Capital, LLC	20/01/20	CI
Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/11/19	CI
Cardax Announces Interim Results from CHASE Clinical Trial	23/09/19	CI
Cardax, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/08/19	CI
Cardax, Inc. announced that it has received $0.75 million in funding	18/07/19	CI
Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	15/05/19	CI
Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	28/03/19	CI
Cardax, Inc. Announces CHASE Clinical Trial Initiated- Rx Development Plans for CDX-101 and CDX-301	28/03/19	CI
Cardax, Inc. Names Paresh N. Soni as Chief Clinical and Regulatory Strategist and Member of Scientific Advisory Board	28/11/18	CI
Cardax, Inc. Announces Sales Results for the Third Quarter and Nine Months of 2018	13/11/18	CI
Cardax, Inc. Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health	02/10/18	CI
Cardax, Inc. Announces Sales Results for the Second Quarter of 2018	13/08/18	CI
Cardax, Inc. Announces Board Appointments	01/06/18	CI
Cardax, Inc. Reports Revenue Results for the First Quarter of 2018	09/05/18	CI

Cardax, Inc. is a consumer health company focused on marketing ZanthoSyn, an astaxanthin dietary supplement for inflammatory health. It seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. It intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CARDAX, INC.	-.--%	0
ELI LILLY AND COMPANY	+31.06%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	327B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+8.12%	165B

Other Pharmaceuticals

Cardax, Inc.

Equities

CDXI

US14141D2018

Pharmaceuticals

Cardax, Inc. has Changed its Ticker to CDXI from CDXID

Latest news about Cardax, Inc.

Chart Cardax, Inc.

Company Profile

Sector Other Pharmaceuticals